• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内镜下黏膜下剥离术联合放疗治疗T1a-MM/T1b-SM期食管鳞状细胞癌的疗效与安全性

[Efficacy and safety of endoscopic submucosal dissection with additional radiotherapy for T1a-MM/T1b-SM esophageal squamous cell carcinoma].

作者信息

Chen Y F, Liu S Q, Li M Y, Chen R, Shi R H

机构信息

Nanjing Medical University, Nanjing 211166, China Department of Gastroenterology, Southeast University Zhongda Hospital, Nanjing 210009, China.

Department of Gastroenterology, Southeast University Zhongda Hospital, Nanjing 210009, China.

出版信息

Zhonghua Yi Xue Za Zhi. 2023 Dec 5;103(45):3676-3682. doi: 10.3760/cma.j.cn112137-20230814-00222.

DOI:10.3760/cma.j.cn112137-20230814-00222
PMID:38018068
Abstract

To clarify the efficacy and safety of endoscopic submucosal dissection (ESD) with additional radiotherapy in T1a-MM/T1b-SM esophageal squamous cell carcinoma (ESCC). A retrospective analysis was conducted on 71 patients with T1a-MM/T1b-SM ESCC admitted to Southeast University Affiliated Zhongda Hospital from January 2015 to December 2019. The patients were divided into two groups based on the treatment method: the ESD group (ESD therapy alone) and the ESD-radiotherapy group (ESD combined radiotherapy). The follow-up duration after ESD was (44±17) months. The difference of disease-free survival (DFS) rate and overall survival (OS) rate between the two groups was compared by survival analysis, and the occurrence of complications was compared. Baseline variables of the two groups were compared and the influencing factors of DFS rate were analyzed by Cox proportional risk regression model. There were 44 patients in the ESD-radiotherapy group [28 males, 16 females, aged (65±7) years] and 27 patients in the ESD group [18 males, 9 females, aged (67±9) years]. The results of survival analysis show that the 1, 3 and 5-year DFS rates of ESD-radiotherapy group were 95.5%, 92.9% and 77.4%, respectively, which were higher than those of ESD group 85.2%, 73.2% and 62.7% (all <0.05). The 1, 3 and 5-year OS rates of the ESD-radiotherapy group were 100%, 94.7% and 94.7%, while those of the ESD group were 96.3%, 96.3% and 79.4%, respectively. The difference was not statistically significant (all >0.05). Cox proportional hazard regression model analysis showed that ESD combined with radiotherapy (=0.19, 95%: 0.04-0.90, =0.037), complete tumor resection (=0.25, 95%: 0.07-0.86, =0.027), and vascular invasion (=12.06, 95%: 1.61-90.26, =0.015) were the influencing factors of DFS rates. The most common complication of ESD was esophageal stenosis, and no grade 3 or higher radiation adverse reactions occurred after combined radiotherapy. ESD combined radiotherapy is an effective and safe therapeutic strategy for patients with T1a-MM/T1b-SM ESCC.

摘要

为明确内镜黏膜下剥离术(ESD)联合放疗治疗T1a-MM/T1b-SM期食管鳞状细胞癌(ESCC)的疗效和安全性。对2015年1月至2019年12月在东南大学附属中大医院住院的71例T1a-MM/T1b-SM期ESCC患者进行回顾性分析。根据治疗方法将患者分为两组:ESD组(单纯ESD治疗)和ESD-放疗组(ESD联合放疗)。ESD术后随访时间为(44±17)个月。通过生存分析比较两组无病生存率(DFS)和总生存率(OS)的差异,并比较并发症的发生情况。比较两组的基线变量,采用Cox比例风险回归模型分析DFS率的影响因素。ESD-放疗组44例[男性28例,女性16例,年龄(65±7)岁],ESD组27例[男性18例,女性9例,年龄(67±9)岁]。生存分析结果显示,ESD-放疗组1、3、5年DFS率分别为95.5%、92.9%和77.4%,高于ESD组的85.2%、73.2%和62.7%(均P<0.05)。ESD-放疗组1、3、5年OS率分别为100%、94.7%和94.7%,ESD组分别为96.3%、96.3%和79.4%,差异无统计学意义(均P>0.05)。Cox比例风险回归模型分析显示,ESD联合放疗(HR=0.19,95%CI:0.04-0.90,P=0.037)、肿瘤完整切除(HR=0.25,95%CI:0.07-0.86,P=0.027)和血管侵犯(HR=12.06,95%CI:1.61-90.26,P=0.015)是DFS率的影响因素。ESD最常见的并发症是食管狭窄,联合放疗后未发生3级及以上放射性不良反应。ESD联合放疗是治疗T1a-MM/T1b-SM期ESCC患者的一种有效且安全的治疗策略。

相似文献

1
[Efficacy and safety of endoscopic submucosal dissection with additional radiotherapy for T1a-MM/T1b-SM esophageal squamous cell carcinoma].内镜下黏膜下剥离术联合放疗治疗T1a-MM/T1b-SM期食管鳞状细胞癌的疗效与安全性
Zhonghua Yi Xue Za Zhi. 2023 Dec 5;103(45):3676-3682. doi: 10.3760/cma.j.cn112137-20230814-00222.
2
Additional radiotherapy following endoscopic submucosal dissection for T1a-MM/T1b-SM esophageal squamous cell carcinoma improves locoregional control.内镜黏膜下剥离术治疗 T1a-MM/T1b-SM 食管鳞癌后加量放疗可提高局部区域控制率。
Radiat Oncol. 2018 Jan 29;13(1):14. doi: 10.1186/s13014-018-0960-y.
3
A retrospective cohort study to observe the efficacy and safety of Endoscopic Submucosal Dissection (ESD) with adjuvant radiotherapy for T1a-MM/T1b-SM Esophageal Squamous Cell Carcinoma (ESCC).一项回顾性队列研究,旨在观察内镜黏膜下剥离术(ESD)联合辅助放疗治疗 T1a-MM/T1b-SM 食管鳞癌(ESCC)的疗效和安全性。
PLoS One. 2024 Feb 22;19(2):e0298792. doi: 10.1371/journal.pone.0298792. eCollection 2024.
4
Endoscopic submucosal dissection with additional radiotherapy in the treatment of T1a esophageal squamous cell cancer: randomized controlled Trial.内镜黏膜下剥离术联合辅助放疗治疗 T1a 期食管鳞癌的随机对照研究。
Endoscopy. 2020 Dec;52(12):1066-1074. doi: 10.1055/a-1198-5232. Epub 2020 Jul 15.
5
Endoscopic Submucosal Dissection Versus Radical Surgery for T1 Superficial Esophageal Cell Carcinoma: a Subgroup Survival Analysis.内镜下黏膜下剥离术与根治性手术治疗T1期浅表性食管癌的亚组生存分析
J Gastrointest Cancer. 2023 Mar;54(1):155-164. doi: 10.1007/s12029-021-00739-2. Epub 2022 Feb 22.
6
Outcomes of Endoscopic Submucosal Dissection vs Esophagectomy for T1 Esophageal Squamous Cell Carcinoma in a Real-World Cohort.内镜黏膜下剥离术与食管切除术治疗 T1 期食管鳞癌的真实世界队列研究结果。
Clin Gastroenterol Hepatol. 2019 Jan;17(1):73-81.e3. doi: 10.1016/j.cgh.2018.04.038. Epub 2018 Apr 25.
7
Therapeutic strategies following endoscopic submucosal dissection for T1a-MM/T1b-SM1 esophageal squamous cell carcinoma: comparisons of long-term outcomes with propensity score-matched analysis.内镜下黏膜下剥离术后治疗T1a-MM/T1b-SM1期食管鳞状细胞癌的策略:倾向评分匹配分析的长期结果比较
Surg Endosc. 2023 Mar;37(3):1761-1770. doi: 10.1007/s00464-022-09683-z. Epub 2022 Oct 11.
8
Radiotherapy Improves Survival of Patients With Lymphovascular Invasion in pT1b Esophageal Squamous Cell Cancer After Endoscopic Submucosal Dissection.放疗可改善内镜黏膜下剥离术后伴有脉管侵犯的 pT1b 期食管鳞癌患者的生存
Am J Gastroenterol. 2023 Aug 1;118(8):1344-1352. doi: 10.14309/ajg.0000000000002257. Epub 2023 Mar 23.
9
Endoscopic Submucosal Dissection Versus Surgery for Superficial Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Survival Analysis.内镜黏膜下剥离术与手术治疗表浅性食管鳞状细胞癌:倾向评分匹配生存分析。
Clin Transl Gastroenterol. 2020 Jul;11(7):e00193. doi: 10.14309/ctg.0000000000000193.
10
Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review.内镜及手术切除 T1a/T1b 食管肿瘤:系统评价。
World J Gastroenterol. 2013 Mar 7;19(9):1424-37. doi: 10.3748/wjg.v19.i9.1424.